Synthego

Executive Summary

Synthego is a privately held biotechnology company based in Redwood City, California, specializing in CRISPR gene editing tools and molecular diagnostics. Founded in 2012, the company provides high-quality synthetic guide RNA (gRNA), engineered nucleases, and isothermal amplification kits for research and clinical applications. By leveraging advanced manufacturing and engineering capabilities, Synthego offers both research-use-only and GMP-grade reagents, positioning itself as a key supplier in the rapidly growing gene editing market. The company's products are essential for accelerating drug discovery, gene therapy development, and diagnostic testing, serving a wide range of academic, biotech, and pharmaceutical customers. Despite being private and without disclosed funding or valuation data, Synthego has established a strong reputation for reliability and scalability in CRISPR reagent supply. Its GMP-grade offerings align with the increasing number of CRISPR-based therapies entering clinical trials, presenting a significant growth opportunity. However, the company faces competition from other reagent suppliers and potential regulatory hurdles. Overall, Synthego is well-positioned to benefit from the expansion of gene editing applications, though its private status limits visibility into financial performance.

Upcoming Catalysts (preview)

• TBDGMP-grade reagent adoption by CRISPR therapy developers75% success
• TBDStrategic partnership or supply agreement with major pharmaceutical company60% success
• TBDLaunch of next-generation synthetic gRNA platform with enhanced performance80% success